Clinovo Ranked #9 Among 494 Biotech by Business Intelligence Company SIGNL
Clinovo Ranked in Top 10 Biotechnology Companies Worldwide for Web Presence and Growth Visibility by the Business Intelligence Company SIGNL.
Sunnyvale, CA (PRWEB) November 21, 2013
SIGNL, a service that tracks the fastest-growing companies worldwide, ranked Clinovo at 9th position among 494 companies in the pharmaceutical, medical device and biotechnology industry. From startups to big businesses, SIGNL measures the success of a company’s engine by aggregating and quantifying evidence of a business growth.
At the 9th position, Clinovo performed significantly well among 494 biotechnology companies, which included some of the leading pharmaceutical, medical device and biotechnology companies in the industry such as Illumina, Ariad Pharmaceuticals, OncoMed, Acorda, Intermune and more.
SIGNL’s sophisticated ranking algorithms measured and compared thousands of companies' key performance indicators and presence on the internet over the last few months. The ranking is based on measurable metrics, including web traffic increase, web mentions, and detailed metrics on social media networks such as Facebook and Twitter. Clinovo's website has increased by 194% over the last three months and Clinovo's Twitter followers grew to 728, a 96% increase in the same period of time.
With this ranking, Clinovo demonstrates its active online presence with strong participation in industry-related discussions. The company regularly releases new white papers, blog posts, and webinars. Also very active offline, the California-based CRO sponsors several national clinical trial events every year including SCDM (Society for Clinical Data Management), PharmaSUG, Outsourcing in Clinical Trials as well as DIA (Drug Information Association). Clinovo also organizes the Silicon Valley BioTalks, a premier local event for pharmaceutical and medical device professionals to build their knowledge and expertise in the clinical trial industry.
Clinovo has a fast-growing customer base in the San Francisco Bay Area, and strive to build long-term relationships with local customers and partners. This fast-growing CRO also has a number of customers on the East Coast, as well as in Europe and Asia. In past years, most of the company's growth has been achieved in the field of Electronic Data Capture (EDC) through Clinovo's open source EDC system ClinCapture. Recently, Clinovo released a set of new advanced features to allow ClinCapture’s users to automate processes. The latest release of ClinCapture reduces overhead for clinical teams and saves them significant time in study conduct. ClinCapture has also been complemented with an integrated eClinical Suite which introduces plug-and-play modules including ePRO (Patient Reported Outcome), CTMS (Clinical Trial Management System), and a new offline mode.
SIGNL founders are veteran tech entrepreneurs and with backgrounds in live-data analysis, financial technology, finance, mobile application development, interface design, and growth hacking (which combines iterative design, extensive user testing, and the application of behavioral psychology to increase user adoption). They have been leaders at IBM Business Consulting Services, Lazard’s Technology Mergers and Acquisitions Group, the World Bank’s International Finance Corporation, and Bloomberg’s Equity Trading Systems Core Team. The SIGNL development team combines diverse backgrounds, with team members holding advanced degrees in business, economics, and computer science. Over eleven-hundred businesses already trust SIGNL to deliver the business intelligence they need. Visit signl.com/company/clinovo/.
Clinovo partners with life science companies to streamline their clinical trials, leveraging years of expertise in systems integration, open source technology and industry standards. Clinovo provides Staffing Solutions, TechTrainings, eClinical Systems and Biometrics Services including Clinical Data Management, Electronic Data Capture, CDISC mapping, and Clinical and Statistical Programming.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11356624.htm